PALO ALTO, Calif., Sept. 6, 2019 /PRNewswire/ -- Kodiak
Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical
company specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that management
will participate in the Morgan Stanley Global Healthcare Conference
in New York, NY on Monday, September 9 at 4:50 p.m. Eastern Time.
A live webcast of the presentation will be available on the
"Investors & Media" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the event.
About Kodiak Sciences Inc.
Kodiak™ is a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component. Kodiak
is based in Palo Alto, CA. For
more information, visit www.kodiak.com.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-300912911.html
SOURCE Kodiak Sciences Inc.